Log in
(Ad)
George Gilder has a shocking message for anybody with money in the bank, with a job that pays in dollars, or who carries a smartphone in their pocket. "Brace yourself," he says, "for the coming $16.8 trillion global 'reboot' ahead." It could change the way you get paid...change the way you save and invest for retirement.

NASDAQ:AKER - Akers Biosciences Stock Price, Forecast & News

$3.50
+0.04 (+1.16 %)
(As of 01/22/2020 01:18 AM ET)
Today's Range
$3.45
Now: $3.50
$3.72
50-Day Range
$2.93
MA: $3.34
$5.93
52-Week Range
$2.67
Now: $3.50
$35.76
Volume340,992 shs
Average Volume286,669 shs
Market Capitalization$1.83 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.89
Akers Biosciences, Inc., together with its subsidiaries, develops, manufactures, and supplies rapid screening and testing products designed to deliver healthcare information to healthcare providers and consumers in the United States, the People's Republic of China, and internationally. The company's marketed products include BreathScan, a disposable breath alcohol detector; BreathScan PRO, a quantitative breath alcohol detection system; METRON, a disposable breath ketone device to monitor ketosis; and BreathScan Lync, a non-invasive, quantitative measurement of biological markers for health and wellness. Its marketed products also include PIFA Heparin/PF4 and PIFA PLUSS PF4 rapid tests for Heparin/PF4 antibodies to detect an allergy to the used blood thinner, Heparin; seraSTAT, a rapid blood cell separator; Tri-Cholesterol 'Check', a rapid test for total and high density lipoprotein cholesterol and estimates low density lipo protein; and BreathScan OxiCHek, a breath test for oxidative stress using the Lync reader and digital app. The company's pipeline products comprise Breath Diabetic Ketoacidosis, a disposable breath ketone device for diabetic monitoring; Breath PulmoHealth 'Check', a suite of breath tests for biomarkers indicating asthma, chronic obstructive pulmonary disease, and lung cancer; PIFA PLUSS Chlamydia, a rapid test for sexually transmitted diseases; and BreathScan KetoChek, a breath test for ketosis using the Lync reader and digital app. Akers Biosciences, Inc. was founded in 1989 and is headquartered in Thorofare, New Jersey.

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AKER
CUSIPN/A
Phone856-848-8698

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.67 million
Book Value$11.21 per share

Profitability

Net Income$-10,850,000.00
Net Margins-359.43%

Miscellaneous

Employees13
Market Cap$1.83 million
Next Earnings Date4/6/2020 (Estimated)
OptionableNot Optionable

Receive AKER News and Ratings via Email

Sign-up to receive the latest news and ratings for AKER and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

Investors looking for the best way to potentially double their money in 2020 -- regardless of whether the overall markets are up or down -- should look no further than these 3 unique stocks.

This Special Report reveals the names of these stocks and provides everything you need to invest right away.

Akers Biosciences (NASDAQ:AKER) Frequently Asked Questions

What is Akers Biosciences' stock symbol?

Akers Biosciences trades on the NASDAQ under the ticker symbol "AKER."

How were Akers Biosciences' earnings last quarter?

Akers Biosciences Inc (NASDAQ:AKER) released its earnings results on Thursday, November, 14th. The medical instruments supplier reported ($1.68) earnings per share (EPS) for the quarter. The medical instruments supplier had revenue of $0.42 million for the quarter. Akers Biosciences had a negative return on equity of 136.53% and a negative net margin of 359.43%. View Akers Biosciences' Earnings History.

When is Akers Biosciences' next earnings date?

Akers Biosciences is scheduled to release their next quarterly earnings announcement on Monday, April 6th 2020. View Earnings Estimates for Akers Biosciences.

Has Akers Biosciences been receiving favorable news coverage?

News articles about AKER stock have trended negative this week, InfoTrie reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Akers Biosciences earned a media sentiment score of -2.2 on InfoTrie's scale. They also assigned news articles about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Akers Biosciences.

Are investors shorting Akers Biosciences?

Akers Biosciences saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 46,400 shares, an increase of 95.8% from the December 15th total of 23,700 shares. Based on an average daily trading volume, of 100,100 shares, the short-interest ratio is currently 0.5 days. Approximately 11.4% of the shares of the company are sold short. View Akers Biosciences' Current Options Chain.

Who are some of Akers Biosciences' key competitors?

What other stocks do shareholders of Akers Biosciences own?

Who are Akers Biosciences' key executives?

Akers Biosciences' management team includes the folowing people:
  • Mr. Howard R. Yeaton Jr., CPA, CEO & Interim CFO (Age 64)
  • Mr. Douglas Carrara, Sr. VP of Global Marketing & Commercial Operations
  • Ms. Pamela E. Hibler, VP of Sales & Distribution
  • Mr. Gary M. Rauch, VP of Fin. & Treasurer (Age 63)

How do I buy shares of Akers Biosciences?

Shares of AKER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Akers Biosciences' stock price today?

One share of AKER stock can currently be purchased for approximately $3.50.

How big of a company is Akers Biosciences?

Akers Biosciences has a market capitalization of $1.83 million and generates $1.67 million in revenue each year. Akers Biosciences employs 13 workers across the globe.View Additional Information About Akers Biosciences.

What is Akers Biosciences' official website?

The official website for Akers Biosciences is http://www.akersbio.com/.

How can I contact Akers Biosciences?

Akers Biosciences' mailing address is 201 GROVE RD, THOROFARE NJ, 08086. The medical instruments supplier can be reached via phone at 856-848-8698 or via email at [email protected]


MarketBeat Community Rating for Akers Biosciences (NASDAQ AKER)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  273 (Vote Outperform)
Underperform Votes:  222 (Vote Underperform)
Total Votes:  495
MarketBeat's community ratings are surveys of what our community members think about Akers Biosciences and other stocks. Vote "Outperform" if you believe AKER will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKER will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel